Impact of hormone therapy on acute radiotherapy toxicity in the treatment of prostate cancer.
OBJECTIVE
To analyze the impact of neoadjuvant hormone therapy (HT) on acute gastrointestinal (GI) and genitourinary (GU) toxicity from radiotherapy (RT).


METHODS
The toxicity rates of 480 consecutive prostate cancer patients were reviewed and compared using the chi2 test. Ordered logit regression analyses were performed including the major demographic, disease, and treatment factors. Although no reduction in acute GI toxicity from HT use was observed (P=0.067), a lower rate of acute GU toxicity was observed (P=0.002). No factor reached statistical significance on regression analysis.


CONCLUSIONS
Observed toxicity rates were similar or lower in patients receiving HT. Thus, increased RT toxicity should not be a concern when deciding to add neoadjuvant HT to RT for prostate cancer.
Jani
A B
AB
Department of Radiation and Cellular Oncology, University of Chicago Hospitals, Chicago, IL 60637, USA. jani@rover.uchicago.edu
Gratzle
J
J
Myers
M
M
D000368:Aged; D000813:Anilides / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001918:Brachytherapy / Q000379:methods; D015331:Cohort Studies; D005485:Flutamide / Q000627:therapeutic use; D041981:Gastrointestinal Tract / Q000187:drug effects* / Q000528:radiation effects; D017273:Goserelin / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D011832:Radiation Injuries; D011878:Radiotherapy / Q000379:methods*; D011879:Radiotherapy Dosage; D012044:Regression Analysis; D013739:Testosterone / Q000378:metabolism; D013997:Time Factors; D014105:Tosyl Compounds; D016896:Treatment Outcome; D014566:Urogenital System / Q000187:drug effects* / Q000528:radiation effects
D000813:Anilides; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D006728:Hormones; D009570:Nitriles; D014105:Tosyl Compounds; D017273:Goserelin; D013739:Testosterone; D005485:Flutamide; C053541:bicalutamide; D016729:Leuprolide